Top

Cancer Causes & Control

Published in:

01-08-2014 | Original Paper

A pooled multisite analysis of the effects of female reproductive hormones on glioma risk

Authors: Bhuma Krishnamachari, Dora Il’yasova, Michael E. Scheurer, Melissa L. Bondy, Margaret Wrensch, Faith G. Davis

Published in: Cancer Causes & Control | Issue 8/2014

Abstract

Purpose

The association between female reproductive factors and glioma risk is unclear, but most published studies have been limited by small sample size. We conducted a pooled multisite study of pre- and postmenopausal women, investigating the effect of female reproductive factors, including hormonal medications.

Methods

Unconditional logistic regression was used to calculate odds ratios (ORs) and 95 % confidence intervals (95 % CIs) assessing the effects of female reproductive factors and female hormonal medications in glioma cases and unrelated controls.

Results

Menarche over the age of 15 as compared to under 12 was associated with a statistically significant risk for glioma (OR 2.00, 95 % CI 1.47–2.71). Use of oral contraceptive pills (OCP) was inversely associated with risk of glioma (OR 0.61, 95 % CI 0.50–0.74), and there was an inverse trend with longer duration of OCP use (p for trend <0.0001). Use of hormone replacement therapy (HRT) was also inversely associated with risk of glioma (OR 0.55, 95 % CI 0.44–0.68), and there was an inverse trend with longer duration of use (p for trend <0.0001). Compared to those reporting neither OCP use nor HRT use, those who reported using both were less likely to have a diagnosis of glioma (OR 0.34, 95 % CI 0.24–0.48).

Conclusions

Female reproductive hormones may decrease the risk for glioma. The association appears to be strongest with greater length of use and use of both HRT and OCP.

Ostrom QT, Gittleman H, Farah P et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States 2006–2010. Neuro-Oncol 15(Suppl 2):ii1–ii56PubMedCrossRef

Preston DL, Ron E, Yonehara S, Kobuke T, Fujii H, Kishikawa M et al (2002) Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J Natl Cancer Inst 94:1555–1563PubMedCrossRef

Yonehara S, Brenner AV, Kishikawa M, Inskip PD, Preston DL, Ron E et al (2004) Clinical and epidemiologic characteristics of first primary tumors of the central nervous system and related organs among atomic bomb survivors in Hiroshima and Nagasaki, 1958–1995. Cancer 101:1644–1654PubMedCrossRef

Garcia-Segura LM, Azocoitia I, DonCarlos LL (2001) Neuroprotection by estradiol. Prog Neurobiol 63:29–60PubMedCrossRef

Santagati S, Melcangi RC, Celotti F, Martini L, Maggi A (1994) Estrogen receptor is expressed in different types of glial cells in culture. J Neurochem 63:2058–2064PubMedCrossRef

Carroll RS, Zhang J, Dashner K, Sar M, Black PM (1995) Steroid hormone receptors in astrocytic neoplasms. Neurosurgery 37:496–503PubMedCrossRef

Khalid MH, Shibata S, Furukawa K, Nadel A, Ammerman MD, Caputy AJ (2004) Role of estrogen receptor-related antigen in initiating the growth of human glioma cells. J Neurosurg 100:923–930PubMedCrossRef

Hatch EE, Linet MS, Zhang J, Fine HA, Shapiro WR, Selker RG et al (2005) Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 114:797–805PubMedCrossRef

Silvera SA, Miller AB, Rohan TE (2006) Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 118:1321–1324PubMedCrossRef

10.

Hochberg F, Toniolo P, Cole P (1990) Nonoccupational risk indicators of glioblastoma in adults. J Neuro-Oncol 8:55–60CrossRef

11.

Cantor KP, Lynch CF, Johnson D (1993) Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 4:505–511PubMedCrossRef

12.

Lambe M, Coogan P, Baron J (1997) Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 72:389–393PubMedCrossRef

13.

Schlehofer B, Blettner M, Preston-Martin S, Niehoff D, Wahrendorf J, Arslan A, Ahlbom A, Choi WN, Giles GG, Howe GR, Little J, Ménégoz F et al (1999) Role of medical history in brain tumor development. Results from the International Adult Brain Tumor Study. Int J Cancer 82:155–160PubMedCrossRef

14.

Huang K, Whelan EA, Ruder AM, Ward EM, Deddens JA, Davis-King KE et al (2004) Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 13:1583–1588PubMed

15.

Felini MJ, Olshan AF, Schroeder JC, Carozza SE, Miike R, Rice T, Wrensch M (2009) Reproductive factors and hormone use and risk of adult glioma. Cancer Causes Control 20:87–96PubMedCentralPubMedCrossRef

16.

Wigertz A, Lönn S, Mathiesen T, Ahlbom A, Hall P, Feychting M et al (2006) Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 164:629–636PubMedCrossRef

17.

Benson VS, Pirie K, Green J, Casabonne D, Beral V, Million Women Study Collaborators (2008) Lifestyle factors and primary glioma and meningioma tumors in the Million Women Study cohort. Br J Cancer 99:185–190PubMedCentralPubMedCrossRef

18.

Wigertz A, Lönn S, Hall P, Auvinen A, Christensen HC, Johansen C, Klaeboe L, Salminen T, Schoemaker MJ, Swerdlow AJ, Tynes T, Feychting M (2008) Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 17:2663–2670PubMedCrossRef

19.

Schlehofer B, Blettner M, Wahrendorf J (1992) Association between brain tumors and menopausal status. J Natl Cancer Inst 84:1346–1349PubMedCrossRef

20.

Qi Z, Shao C, Zhang X, Hui G, Zhong W (2013) Exogenous and endogenour hormones in relation to glioma in women: a meta-analysis of 11 case–control studies. PLoS ONE 8(7):e68695PubMedCentralPubMedCrossRef

21.

Kabat GC, Park Y, Hollenbeck AR, Schatzkin A, Rohan TE (2011) Reproductive factors and exogenous hormone use and risk of adult glioma in women in the NIH-AARP Diet and Health Study. Int J Cancer 128(4):944–950. doi:10.1002/ijc.25413 PubMedCentralPubMedCrossRef

22.

Amirian E, Scheurer ME, Bondy ML (2010) The association between birth order, sibship size and glioma development in adulthood. Int J Cancer 126:2752–2756PubMedCentralPubMed

23.

Wiemels JL, Wiencke JK, Kelsey KT, Moghadassi M, Rice T, Urayama KY et al (2007) Allergy-related polymorphisms influence glioma status and serum IgE levels. Cancer Epidemiol Biomarkers Prev 16:1229–1235PubMedCrossRef

24.

Wrensch M, McMillan A, Wiencke J, Wiemels J, Kelsey K, Patoka J et al (2007) Nonsynonymous coding single-nucleotide polymorphisms spanning the genome in relation to glioblastoma survival and age at diagnosis. Clin Cancer Res 13:197–205PubMedCrossRef

25.

Zisakis A, Piperi C, Themistocleous MS, Korkolopoulou P, Boviatsis EI, Sakas DE et al (2007) Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 39:99–105PubMedCrossRef

26.

Berger A (2000) Th1 and Th2 responses: what are they? BMJ 321:424PubMedCentralPubMedCrossRef

27.

Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D (2006) Antitumoral activity of interferon-gamma involved in impaired immune function in cancer patients. Curr Drug Metab 7:599–612PubMedCrossRef

28.

Schwartzbaum J, Jonsson F, Ahlbom A, Preston-Martin S, Lönn S, Söderberg KC et al (2003) Cohort studies of association between self-reported allergic conditions, immune-related diagnoses and glioma and meningioma risk. Int J Cancer 106:423–428PubMedCrossRef

29.

Girón-González JA, Moral FJ, Elvira J, García-Gil D, Guerrero F, Gavilán I et al (2000) Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 143:31–36PubMedCrossRef

30.

Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H (2003) Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 170:1548–1555PubMedCrossRef

31.

Vural P, Akgul C, Canbaz M (2006) Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res 54:298–302PubMedCrossRef

32.

Kamada M, Irahara M, Maegawa M, Ohmoto Y, Murata K, Yasui T et al (2001) Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. Gynecol Obstet Invest 52:82–88PubMedCrossRef

33.

Kumru S, Yildiz FM, Godekmerdan A, Kutlu S, Yilmaz B, Gurates B (2008) Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial. Arch Gynecol Obstet 277:489–493PubMedCrossRef

34.

Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG, Agnantis NJ (2004) Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol 130:405–410PubMedCrossRef

35.

Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, Polyzoidis K et al (2006) Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol 77:17–23PubMedCrossRef

36.

Gonzalez-Aguero G, Ondarza R, Gamboa-Dominguez A, Cerbon MA, Camacho-Arroyo I (2001) Progesterone receptor isoforms expression pattern in human astrocytomas. Brain Res Bull 56:43–48PubMedCrossRef

37.

Inoue T, Akahira J, Suzuki T, Darnel AD, Kaneko C, Takahashi K et al (2002) Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 87:5325PubMedCrossRef

Title: A pooled multisite analysis of the effects of female reproductive hormones on glioma risk
Authors: Bhuma Krishnamachari
Dora Il’yasova
Michael E. Scheurer
Melissa L. Bondy
Margaret Wrensch
Faith G. Davis
Publication date: 01-08-2014
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 8/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-014-0400-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2014

Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage

Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data

Erratum to: Childhood acute leukemia, maternal beverage intake during pregnancy, and metabolic polymorphisms

Assessment of a fully automated, high-throughput mammographic density measurement tool for use with processed digital mammograms

The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort

History of periodontal disease diagnosis and lung cancer incidence in the Women’s Health Initiative Observational Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer